Search

Research has been conducted on Lactococcus lactis (Delta)thyA mutants. Results demonstrate that enzyme synthesis is important for the rate of nonreplicating L. lactis acidification and that the incorporation of nonspecific ATPase activity into nonreplicating cells may be useful for the lactic acid flux increase.

Research has been conducted on the genes encoding F (sub)1 -ATPase. Results indicate that the expression of these genes induces uncoupling of glycolysis from biomass production in Lactococcus lactis.

Research has been conducted on Lactococcus lactis gene thyA which encodes thymidylate synthase. Results indicate that acidification by the thyA mutant is unaffected by bacteriophage.

Bifidobacterium animalis subsp. lactis BB-12 is a commercially available probiotic strain used throughout the world in a variety of functional foods and dietary supplements. The benefits of BB-12 have been documented in a number of independent clinical trials. Determination of the complete genome sequence reveals a single circular chromosome of 1,942,198 bp with 1,642 predicted protein-encoding genes, 4 rRNA operons, and 52 tRNA genes. Knowledge of this sequence will lead to insight into the specific features which give this strain its probiotic properties. doi: 10.1128/JB.00109-10

Reports on the increasing acidification of nonreplicating Lactococcus lactis thymidylate synthase mutants by incorporating ATPase activity. Correlation between optical density and cell dry weight for nonreplicating cells; Nonreplicating thymidylate synthase and the rate of acidification increases; Decreased in the biomass yield of exponentially growing cells with the incorporation of the ATPase activity.

Examines the bacteriophage resistance of a thyA mutant Lactococcus lactis blocked in DNA replication. Results of the DNA sequencing; Construction of gene inactivation vector; Acidification of the MBP71 sequence.

Myeloid and lymphoid malignancies are postulated to have distinct pathogenetic mechanisms. The recent observation that patients with a myeloproliferative neoplasm have an increased risk of developing lymphoproliferative malignancy has challenged this assumption. We collected a nationwide cohort of patients with both malignancies. Patients diagnosed in 1990-2015 were identified through the national Danish Pathology Registry. We identified 599 patients with myeloproliferative neoplasm and a concomitant or subsequent diagnosis of lymphoma. Histopathological review of the diagnostic samples from each patient led to a final cohort of 97 individuals with confirmed dual diagnoses of myeloproliferative neoplasm and lymphoma. The age range at diagnosis was 19-94 years (median: 71 years). To avoid the inclusion of cases of therapy-induced myeloproliferative neoplasm occurring in patients previously treated for lymphoma, only patients with myeloproliferative neoplasm diagnosed unequivocally before the development of lymphoma were included. The average time interval between the diagnoses of the two malignancies was 1.5 years. In the majority of patients (90%) both diagnoses were established within 5 years from each other. Among the lymphoma entities, the frequency of peripheral T-cell lymphomas was markedly increased. Interestingly, all but one of the T-cell lymphomas were of angioimmunoblastic type. These findings suggest that myeloproliferative neoplasm and lymphoproliferative malignancy developing in the same patient may have common pathogenetic events, possibly already at progenitor level. We believe that the molecular characterization of the newly developed biorepository will help to highlight the mechanisms driving the genesis and clonal evolution of these hematopoietic malignancies.